Hepatocellular adenoma: what we know, what we do not know, and why it matters
| العنوان: | Hepatocellular adenoma: what we know, what we do not know, and why it matters |
|---|---|
| المؤلفون: | Christine Sempoux, Charles Balabaud, Paulette Bioulac-Sage, Annette S. H. Gouw |
| المصدر: | Histopathology. 80:878-897 |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | medicine.medical_specialty, Carcinoma, Hepatocellular, Histology, business.industry, Liver Neoplasms, Hemorrhage, General Medicine, Hepatocellular adenoma, medicine.disease, Adenoma, Liver Cell, Pathology and Forensic Medicine, Patient management, Natural history, Rare tumor, Cell Transformation, Neoplastic, medicine, Etiology, Humans, Hedgehog Proteins, Prospective Studies, Major complication, Intensive care medicine, business |
| الوصف: | In the last two decades there has been significant progress in research on and diagnosis of hepatocellular adenoma (HCA), resulting in the establishment of a molecular and immunohistological HCA classification. This review aims to fine-tune the current expertise in order to enhance the histopathological diagnostic possibilities, by refining issues that are already known, addressing diagnostic difficulties, and identifying still unknown aspects of HCA. We discuss novel methods to identify HCA subtypes, in particular the sonic hedgehog HCAs and the interpretation of glutamine synthetase patterns for the recognition of β-catenin-mutated HCAs. The major complications of HCAs, i.e. bleeding and malignant transformation, are considered, including the dilemmas of atypical and borderline lesions. HCAs in different clinical and geographical settings, e.g. pregnancy, cirrhosis and non-western countries, are also discussed. The natural history of the different HCA subtypes in relation to age, sex and risk factors is a feature that is still insufficiently investigated. This is also true for the risks of clinical bleeding and malignant transformation in association with HCA subtypes. As HCA is a relatively rare tumour, a multicentre and multidisciplinary approach across geographical boundaries will be the appropriate method to establish prospective programmes with which to identify, classify and manage HCAs, focusing on several aspects, e.g. aetiology, underlying liver disease, complications, regression, and growth. Updating what we know and identifying and addressing what we do not know matters for optimal patient management. |
| تدمد: | 1365-2559 0309-0167 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::079e7a9e544344ec8ea581897bcf2dbcTest https://doi.org/10.1111/his.14605Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....079e7a9e544344ec8ea581897bcf2dbc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652559 03090167 |
|---|